Table 1.
Characteristics | Total (n = 17,881) | Treatment post-index event | ||
---|---|---|---|---|
Untreated with LLT 6 months post-index event (n = 1096) | Moderate-/low-intensity LLT (n = 8863) | High-intensity LLT (n = 7922) | ||
Age years, mean (SD) | 67.1 (9.8) | 70.9 (8.3) | 68.5 (9.1) | 65.0 (10.3) |
Male, n (%) | 12,780 (71.5) | 705 (64.3) | 6069 (68.5) | 6006 (75.8) |
Comorbidities, pre-index, n (%) | ||||
ACS | 10,063 (56.3) | 356 (32.5) | 3574 (40.3) | 6133 (77.4) |
IS | 4053 (22.7) | 395 (36.0) | 2989 (33.7) | 669 (8.4) |
PAD | 3765 (21.1) | 345 (31.5) | 2300 (26.0) | 1120 (14.1) |
Diabetes | 4368 (24.4) | 372 (33.9) | 2154 (24.3) | 1842 (23.3) |
Lipid metabolism disturbances | 5872 (32.8) | 164 (15.0) | 2525 (28.5) | 3183 (40.2) |
Obesity | 987 (5.5) | 37 (3.4) | 352 (4.0) | 598 (7.5) |
Hypertension | 9014 (50.4) | 481 (43.9) | 4453 (50.2) | 4080 (51.5) |
Previous myocardial infarction | 7877 (44.1) | 253 (23.1) | 2407 (27.2) | 5217 (65.9) |
Other forms of ischemic heart disease | 9298 (52.0) | 405 (37.0) | 3865 (43.6) | 5028 (63.5) |
Heart failure | 2686 (15.0) | 253 (23.1) | 1259 (14.2) | 1174 (14.8) |
Cerebrovascular disease | 4469 (25.0) | 415 (37.9) | 2968 (33.5) | 1086 (13.7) |
Chronic renal disease | 1476 (8.3) | 209 (19.1) | 746 (8.4) | 521 (6.6) |
Previous coronary artery bypass graft | 2636 (14.7) | 95 (8.7) | 1075 (12.1) | 1466 (18.5) |
Previous coronary angioplasty | 7085 (39.6) | 129 (11.8) | 2278 (25.7) | 4678 (59.1) |
Cerebral revascularization procedures | 1260 (7.0) | 73 (6.7) | 860 (9.7) | 327 (4.1) |
Antihypertensive medications at index | 3957 (22.1) | 226 (20.6) | 2114 (23.9) | 1617 (20.4) |
Anti-diabetic medications at index | 639 (3.6) | 54 (4.9) | 390 (4.4) | 195 (2.5) |
Anti-thrombotic medications at index | 15,179 (84.9) | 612 (55.8) | 7508 (84.7) | 7059 (89.1) |
LDL-C and HDL-C measurements at index event were not available
ACS acute coronary syndrome, HDL-C high-density lipoprotein cholesterol, IS ischemic stroke/transient ischemic attack, LDL-C low-density lipoprotein cholesterol, LLT lipid-lowering therapy, PAD peripheral artery disease, SD standard deviation